These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 16951208)

  • 1. Sequential valproic acid/all-trans retinoic acid treatment reprograms differentiation in refractory and high-risk acute myeloid leukemia.
    Cimino G; Lo-Coco F; Fenu S; Travaglini L; Finolezzi E; Mancini M; Nanni M; Careddu A; Fazi F; Padula F; Fiorini R; Spiriti MA; Petti MC; Venditti A; Amadori S; Mandelli F; Pelicci PG; Nervi C
    Cancer Res; 2006 Sep; 66(17):8903-11. PubMed ID: 16951208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical trial of valproic acid and all-trans retinoic acid in patients with poor-risk acute myeloid leukemia.
    Bug G; Ritter M; Wassmann B; Schoch C; Heinzel T; Schwarz K; Romanski A; Kramer OH; Kampfmann M; Hoelzer D; Neubauer A; Ruthardt M; Ottmann OG
    Cancer; 2005 Dec; 104(12):2717-25. PubMed ID: 16294345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia.
    Kuendgen A; Knipp S; Fox F; Strupp C; Hildebrandt B; Steidl C; Germing U; Haas R; Gattermann N
    Ann Hematol; 2005 Dec; 84 Suppl 1():61-6. PubMed ID: 16270213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia.
    Kuendgen A; Schmid M; Schlenk R; Knipp S; Hildebrandt B; Steidl C; Germing U; Haas R; Dohner H; Gattermann N
    Cancer; 2006 Jan; 106(1):112-9. PubMed ID: 16323176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid.
    Pilatrino C; Cilloni D; Messa E; Morotti A; Giugliano E; Pautasso M; Familiari U; Cappia S; Pelicci PG; Lo Coco F; Saglio G; Guerrasio A
    Cancer; 2005 Jul; 104(1):101-9. PubMed ID: 15895376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic induction of folate receptor beta by all-trans retinoic acid and histone deacetylase inhibitors in acute myelogenous leukemia cells: mechanism and utility in enhancing selective growth inhibition by antifolates.
    Qi H; Ratnam M
    Cancer Res; 2006 Jun; 66(11):5875-82. PubMed ID: 16740727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valproic acid and all-trans retinoic acid for the treatment of elderly patients with acute myeloid leukemia.
    Raffoux E; Chaibi P; Dombret H; Degos L
    Haematologica; 2005 Jul; 90(7):986-8. PubMed ID: 15996941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valproic acid and all-trans retinoic acid: meta-analysis of a palliative treatment regimen in AML and MDS patients.
    Bellos F; Mahlknecht U
    Onkologie; 2008 Nov; 31(11):629-33. PubMed ID: 19145098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia.
    Ferrara FF; Fazi F; Bianchini A; Padula F; Gelmetti V; Minucci S; Mancini M; Pelicci PG; Lo Coco F; Nervi C
    Cancer Res; 2001 Jan; 61(1):2-7. PubMed ID: 11196162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the relationship between Scl transcription factor complex protein expression patterns and the effects of LiCl on ATRA-induced differentiation in blast cells from patients with acute myeloid leukemia.
    Rice AM; Holtz KM; Karp J; Rollins S; Sartorelli AC
    Leuk Res; 2004 Nov; 28(11):1227-37. PubMed ID: 15380350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Valproic acid for the treatment of myeloid malignancies.
    Kuendgen A; Gattermann N
    Cancer; 2007 Sep; 110(5):943-54. PubMed ID: 17647267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells.
    Trus MR; Yang L; Suarez Saiz F; Bordeleau L; Jurisica I; Minden MD
    Leukemia; 2005 Jul; 19(7):1161-8. PubMed ID: 15902297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. beta2 Integrins are characteristically absent in acute promyelocytic leukemia and rapidly upregulated in vivo upon differentiation with all-trans retinoic acid.
    Wu JJ; Cantor A; Moscinski LC
    Leuk Res; 2007 Jan; 31(1):49-57. PubMed ID: 16764927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. All-trans retinoic acid as a single agent induces complete remission in a patient with acute leukemia of M2a subtype.
    Chen Z; Wang Y; Wang W; Gong J; Xue Y
    Chin Med J (Engl); 2002 Jan; 115(1):58-61. PubMed ID: 11930660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hematologic improvement and response in elderly AML/RAEB patients treated with valproic acid and low-dose Ara-C.
    Corsetti MT; Salvi F; Perticone S; Baraldi A; De Paoli L; Gatto S; Pietrasanta D; Pini M; Primon V; Zallio F; Tonso A; Alvaro MG; Ciravegna G; Levis A
    Leuk Res; 2011 Aug; 35(8):991-7. PubMed ID: 21474179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [All-trans retinoic acid was effective for marked skin infiltration in a relapsed acute myelogenous leukemia (AML-M2) patient with t(12; 17)].
    Sawanobori M; Nakagawa Y; Inoue Y; Suzuki K; Kanno K; Hashimoto S; Takemura T
    Rinsho Ketsueki; 1998 May; 39(5):363-8. PubMed ID: 9637886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenomic changes during leukemia cell differentiation: analysis of histone acetylation and cytosine methylation using CpG island microarrays.
    Nouzova M; Holtan N; Oshiro MM; Isett RB; Munoz-Rodriguez JL; List AF; Narro ML; Miller SJ; Merchant NC; Futscher BW
    J Pharmacol Exp Ther; 2004 Dec; 311(3):968-81. PubMed ID: 15302897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Downregulation of c-Myc is critical for valproic acid-induced growth arrest and myeloid differentiation of acute myeloid leukemia.
    Cheng YC; Lin H; Huang MJ; Chow JM; Lin S; Liu HE
    Leuk Res; 2007 Oct; 31(10):1403-11. PubMed ID: 17445886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disease-stabilizing treatment with all-trans retinoic acid and valproic acid in acute myeloid leukemia: serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti-leukemic treatment.
    Fredly H; Reikvam H; Gjertsen BT; Bruserud O
    Am J Hematol; 2012 Apr; 87(4):368-76. PubMed ID: 22374841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic heterochromatin markers distinguish terminally differentiated leukocytes from incompletely differentiated leukemia cells in human blood.
    Popova EY; Claxton DF; Lukasova E; Bird PI; Grigoryev SA
    Exp Hematol; 2006 Apr; 34(4):453-62. PubMed ID: 16569592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.